医学                        
                
                                
                        
                            伦瓦提尼                        
                
                                
                        
                            吉西他滨                        
                
                                
                        
                            化疗                        
                
                                
                        
                            放射科                        
                
                                
                        
                            肿瘤科                        
                
                                
                        
                            内科学                        
                
                                
                        
                            肝细胞癌                        
                
                                
                        
                            索拉非尼                        
                
                        
                    
            作者
            
                Qinqin Liu,Xianhuan Yu,Qibin Tang,Dong Chen,Rui Zhang,Chao Liu,Xiang-de Shi            
         
                    
        
    
            
            标识
            
                                    DOI:10.1097/cad.0000000000001519
                                    
                                
                                 
         
        
                
            摘要
            
            Perihilar cholangiocarcinoma is a refractory malignancy with an unfavorable prognosis and a high probability of recurrence. Systemic chemotherapy is critical for palliative treatment, but effective therapeutic strategies for perihilar cholangiocarcinoma after first-line chemotherapy failure are scarce. Here, we introduced a sustained benefit following sintilimab combined with lenvatinib plus S-1 in a patient with recurrent perihilar cholangiocarcinoma. A 52-year-old female patient was admitted to our hospital due to yellow skin and sclera, and further radiological examination revealed perihilar cholangiocarcinoma. The patient underwent surgery and histopathological results confirmed moderately differentiated adenocarcinoma with metastatic lymph nodes. Postoperative adjuvant chemotherapy with gemcitabine and S-1 was given. One year after surgery, the patient experienced hepatic recurrence. Then, she received radiofrequency ablation combined with gemcitabine and cisplatin. Unfortunately, radiological assessment revealed progressive disease with multiple liver metastases after treatment. Subsequently, she received sintilimab combined with lenvatinib plus S-1 and the lesions were completely regressed following 14 cycles of combination therapy. The patient recovered well without disease recurrence at the last follow-up. Sintilimab combined with lenvatinib plus S-1 may be an alternative therapeutic option for chemotherapy-refractory perihilar cholangiocarcinoma, and further evaluation in a larger number of patients is needed.
         
            
 
                 
                
                    
                    科研通智能强力驱动
Strongly Powered by AbleSci AI